{"doi":"10.1016/j.atherosclerosis.2009.06.003","title":"Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease","abstract":null,"journal":"Atherosclerosis","year":2009,"id":611227,"datarank":0.6394019815561974,"base_score":4.2626798770413155,"endowment":4.2626798770413155,"self_citation_contribution":0.6394019815561974,"citation_network_contribution":0.0,"self_endowment_contribution":0.6394019815561974,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":70,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1572946,"name":"Namita Malik","orcid":null,"position":1,"is_corresponding":false},{"id":1572947,"name":"Ajay Bahl","orcid":null,"position":2,"is_corresponding":false},{"id":1572948,"name":"Veena Dhawan","orcid":null,"position":3,"is_corresponding":false},{"id":499237,"name":"Nitin Mahajan","orcid":"0000-0002-0907-6410","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease","abstract":"<h4>Objective</h4>Inflammation participates in atherosclerosis from its inception onwards. RAGE (receptor for advanced glycation end products) and its natural pro-inflammatory ligand, EN-RAGE (extracellular newly identified RAGE-binding protein) have been implicated in various inflammatory diseases. In present study, we determined the expression of RAGE and EN-RAGE in peripheral blood mononuclear cells (PBMCs) of subjects with pre-mature coronary artery disease (CAD) for the first time.<h4>Methods and results</h4>The study patients were angiographically proven non-diabetic patients with pre-mature CAD (Group I; N=100) and control group comprised of subjects with coronary risk factors and without coronary artery lesions (Group II; N=40). Semi-quantitative RT-PCR was performed to determine transcriptional expression of RAGE and EN-RAGE in PBMCs. Soluble RAGE (sRAGE) and C-reactive protein (hsCRP) levels were determined in serum of all study subjects using immunoassays. A significantly increased transcriptional expression of RAGE and EN-RAGE in PBMCs (p<0.01) of Group I patients was observed. Increased circulating hsCRP (p<0.01) levels and decreased sRAGE (p<0.01) levels were observed in Group I as compared with the Group II subjects. Severity of disease determined by Gensini score was found to be positively correlated with transcriptional expression of RAGE (r=0.530) and EN-RAGE (r=0.323). EN-RAGE expression revealed a strong association with RAGE (r=0.326), hsCRP (r=0.251) and a negative association with sRAGE (r=-0.222).<h4>Conclusions</h4>Increased expression of RAGE and EN-RAGE in non-diabetic pre-mature CAD and various associations discussed may amplify several cellular perturbations and thus significantly contribute to the pathophysiology of CAD.","is_dataset_classified":null,"base_score":4.2626798770413155,"endowment":4.2626798770413155,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19576587","pmcid":null,"openalex_id":"https://openalex.org/W2052583421","authors":[],"funders":[],"total_grants":0,"fwci":2.4344,"citation_percentile":0.87082792,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":12},{"year":2014,"count":8},{"year":2015,"count":10},{"year":2016,"count":2},{"year":2017,"count":3},{"year":2018,"count":2},{"year":2019,"count":4},{"year":2020,"count":3},{"year":2021,"count":3},{"year":2022,"count":2},{"year":2023,"count":3},{"year":2024,"count":4},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S002191500900433X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S002191500900433X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.atherosclerosis.2009.06.003","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19576587","host_type":"repository"}],"fields_of_study":["Advanced Glycation End Products research","Inflammation biomarkers and pathways","Atherosclerosis and Cardiovascular Diseases","Adult","Age of Onset","Biomarkers","C-Reactive Protein","Case-Control Studies","Coronary Angiography","Coronary Artery Disease","Cross-Sectional Studies","Female","Humans","Inflammation Mediators","Ligands","Logistic Models","Male","Middle Aged","RNA, Messenger","Receptor for Advanced Glycation End Products","Receptors, Immunologic","Reverse Transcriptase Polymerase Chain Reaction","Risk Assessment","Risk Factors","S100 Proteins","S100A12 Protein","Severity of Illness Index","Transcriptional Activation","Up-Regulation","Young Adult"],"mesh_terms":["S100A12 Protein","Receptor for Advanced Glycation End Products","Adult","C-Reactive Protein","Coronary Artery Disease","Cross-Sectional Studies","Female","Humans","Ligands","Male","Middle Aged","S100 Proteins","Receptors, Immunologic","Risk Factors","RNA, Messenger","Severity of Illness Index","Biomarkers","Transcriptional Activation","Up-Regulation","Logistic Models","Case-Control Studies","Coronary Angiography","Age of Onset","Risk Assessment","Inflammation Mediators","Reverse Transcriptase Polymerase Chain Reaction","Young Adult"],"keywords":["Rage (emotion)","Glycation","Coronary artery disease","Medicine","Receptor","HMGB1","Advanced glycation end-product","Disease","Inflammation","Internal medicine","Immunology","Biology","Neuroscience"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T17:03:29.365784Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}